AsymBio, a strategic business of Asymchem Group, focuses exclusively on biopharmaceutical CDMO services (stock code: 002821.SZ / 6821.HK). Leveraging advanced technology platforms and extensive project experience, AsymBio provides global clients with one-stop CDMO solutions for various novel conjugated drugs, antibodies, and recombinant protein drugs. Its capabilities span early-stage research, process development, toxicology batches, clinical batches, and commercial-scale manufacturing. Asymbio is committed to becoming a trustworthy partner for global biopharmaceutical clients, empowering biopharmaceutical innovation worldwide and accelerating the drug commercialization process.